Turkey: PIOZON Case Summary - 2012

Last Updated: 21 February 2019
Practice Guide by Deris IP Attorneys


Jurisdiction: Turkey
Subject Heading: Similarity of Marks
Case Name and Citation:

1- (4th Ankara Court of Intellectual and Industrial Rights, Case No. 2011/431- Decision No.2012/28, March 14, 2012)
2- (Supreme Court 11th Civil Chamber, Decision No: E.2009/13331- 2011/5967, May 16, 2011)





Marks Associated with Goods/Services:

The plaintiff has sought to register in Turkey the trademark PLIAZON through international application No: 826998 in respect of “Pharmaceutical preparations for human use in the field of oncology” in class 05.

The defendant (2) ÝSTANBUL GALENOS ECZ DEPOSU TÝCARET VE SANAYÝ AÞ is the registrant of the trademark reg. no: 2003/02736 for PIOZON trademark registered in respect of all goods in sub-classes of classes 05, 16 and 35.

Nature of Case:

The action has been instituted for the withdrawal of the final decision of the Turkish Patent Institute where the application of PLIAZON trademark was rejected due to prior registration for PIOZON trademark on the basis of undistinguishable similarity.

Prior Decisions:

The Defendant’s opposition against the publication of PLIAZON trademark application based on his prior PIZON trademark was accepted by the Turkish Patent Institute due to similarity of trademarks in the sense Article 8/1(b)1, Decree-Law no. 556 For Protection of Trademarks. Upon objection against this refusal decision Higher Council of the Turkish Patent Institute upheld that the trademarks in question are similar, accordingly the application of PLIAZON trademark would be rejected.

Overview of Decision and Ruling:

The plaintiff has asserted the following points in his petition:
- The importance of consumers which the trademarks address is an essential point in the evaluation of the similarity
- The applied PLIAZON trademark is the name of a drug which would be used in the treatment of cancer and therefore does have to be sold with prescription necessarily
- ZON indication has a weak distinctive character, therefore the holder of a trademark which is bearing such an indication must bear the consequences of it.
- The usage are of the trademarks in question namely the drugs are different
and requested the cancellation of the Higher Council Decision ruling that the PLIAZON and PIOZON trademarks are indistinguishably similar to each other.

The First defendant THE TURKISH PATENT INSTITUTE’s petition against the above assertions has been motivated in that:
- The trademarks in question are similar to each other in the sense of Article 8/b(1)
- The specifications covered by the trademarks are identical and similar
- The similarity does not arise from a use of an active substance of the drugs in question as an indication
- The trademarks in question may lead even the doctors and pharmacist who do pay high attention to confusion
therefore the prior decision of Higher Council is well-grounded and the present case must be rejected.

The second defendant GALENOS put forward in his petition that:
- The trademark of the plaintiff is indistinguishably similar to his prior trademark due to covering same specifications
- The similarity between trademarks may lead the consumers to confusion, therefore there is likelihood of confusion.

In the light of the evidences submitted by the parties and of the experts report which are in plaintiff’s favor, The 1st Instance Court contrary to the conclusions of the Experts report retained that:
- since the PLIAZON trademark is applied for “Pharmaceutical preparations for human use in the field of oncology” goods in class 05 and the prior PIOZON trademark is registered in all sub-classes of 05, 16 and 35, the trademarks overlaps in the first sub-classes of class 05.
- the trademarks in question are not identical but similar in the sense of Article 8/1(b) in respect of visual and phonetic aspects due to common initial P letter and last three ZON letters as well as two letter difference of L and A.
- the consumers may consider that the trademarks belong to the same or associated company
- even though PLIAZON trademark is applied for the “Pharmaceutical preparations for human use in the field of oncology”, it has revealed that there is no application for any regulatory authorization for both PLIAZON and PIOZON trademarks before the Ministry of Health, accordingly the active ingredients of the drugs are not known. Moreover, the PIOZON trademark is registered for the all sub-classes in class 05, it was not determined that on which drugs the trademark would be used.
- despite the fact that the trademarks used on drugs are firstly subject to authorization by the Ministry of Health and then sold through pharmacists upon prescription written by doctors, there is no special regulation or provision for this practice in the Article 8/b of the Decree-Law no. 556 for the protection of the trademarks, so this fact can not be a point to be taken into consideration for assessing similarity.
- the ZON indication is not a weak indication since such a weakness is only acceptable on the condition that a trademark consist of an indication which indicates an active substance in the drug.
- to oblige the doctors, pharmacist and the patients to pay high attention in distinguishing the trademarks does not comply with the “distinctiveness” function of the trademark while there are no technical necessities and there are many options in choosing another distinctive indication.
and ruled that there is likelihood of confusion between the trademarks PLIAZON and PIOZON thus upholding the TPI’s decision of refusal.

The decision was appealed by the plaintiff and the Supreme Court with its decision (2) overturned the decision of the 1st Instance Court on grounds that:
- since PLIAZON trademark would be used on drugs used in the treatment of cancer, it is not possible for such a drug to be sold without control of doctor and without prescription. In this respect its use can not be subject to same conditions as for non-prescription drugs.
- In accordance with the above-mentioned point, it was determined in two experts reports that there is no likelihood of confusion between the trademarks in taking into account the involvement of doctors and pharmacists in the choice and use of the drugs under the trademark PLIAZON.

Upon the reverse of the judgment, the First Instant Court upheld in compliance with the Supreme Court decision and ruled the cancellation of subject Higher Council decision and the continuation of the application process of PLIAZON trademark since there is not a indistinguishable similarity between PLIAZON and PIOZON trademark.

Importance of Case:

This case is important because according to the current practice of Turkish Trademark Law, similarity of goods and services is evaluated on the basis of sub-classes. In other words, even though the goods and services are different, they are deemed similar in case they fall under the same subclasses. With this decision, the Court ruled that even though the goods of PLIAZON trademark, “Pharmaceutical preparations for human use in the field of oncology” fall under the first sub-class of class 05 which was covered wholly by PIOZON trademark, the goods of the trademark must not be evaluated as similar considering the fact that the drugs for treatment of cancer can only be bought upon prescription written by doctors.

1 Upon opposition by the proprietor of an application for registration of a trademark or of a registered trademark, the trademark applied for shall not be registered subject to the following conditions:

b)Where the trademark applied for is identical or similar to a registered trademark or to a trademark applied for registration under a prior date of filing and the registration is sought for identical or similar goods or services in that the likelihood of confusion includes the likelihood of association with the registered trademark or with the trademark applied for registration under a prior date of filing.

This document is not intended to create an attorney-client relationship. You should not act or rely on any information in this document without first seeking legal advice. This material is intended for general information purposes only and does not constitute legal advice. If you have any specific questions on any legal matter, you should consult a professional legal services provider.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Contact the Author?
Click here to email the Author
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Other Turkey Advice Centres
Competition and Antitrust
Privacy and Data Protection
More Advice Centers
Useful Resources
Translation by Deris Patents & Trademarks Agency Limited
Translation by Deris Patents & Trademarks Agency Limited
Translation by Deris Patents & Trademarks Agency Limited
Translation by Deris Patents & Trademarks Agency Limited
The national Turkey group for the International Association for the Protection of Intellectual Property.
Upcoming Events
This site provides access to information about meetings held at WIPO and related documents comprising a detailed meeting calendar and a powerful document search facility.
A calendar of past and future events held by the Turkish Patent Institute.
Information about events and classroom training, online training, the European qualifying examination, and other materials.
From the Annual Meeting to local forums, roundtables and digital learning, INTA's Programs and Events help you stay up to date on issues that affect your brands.
Font Size:
Mondaq on Twitter
Mondaq Sign Up
Gain free access to lawyers expertise from more than 250 countries.
Email Address
Company Name
Confirm Password
Mondaq Newsalert
Select Topics
Select Regions
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions